Next-generation imaging development for nanoparticle biodistribution measurements.
As nanotechnologies move closer to use in humans, quantitative imaging methods will play a vital role in answering questions of biodistribution. Accurate knowledge of the location and quantity of in vivo nanoconstructs and carriers is a challenging task, and new methods of quantitative imaging at appropriate resolutions are being developed and tested. Sustaining simultaneous advancement in both imaging development and nanotechnology research requires multidisciplinary research teams conducting experiments with interconnected goals. On an even greater scale, networks of multidisciplinary teams focused on similar issues of imaging and probe development offer opportunities for leveraging resources, as well as providing a forum for sharing ideas and creating consensus on solutions to common challenges. The Network for Translational Research (NTR): Optical Imaging in Multimodal Platforms from the National Cancer Institute is just such a network. Four multidisciplinary centers are accepting the challenges of developing and optimizing multimodal imaging hardware and software along with imaging probe development. These efforts are similar to the efforts that will be required for future studies of in vivo nanoparticle biodistribution. In addition to technology development and optimization, the network is organized to confront the challenges of validation of the imaging hardware and associated imaging agents, similar to the methods needed for validating nanomedicine.
Tandon
Pushpa
P
National Cancer Institute, National Institutes of Health, Cancer Imaging Program, Bethesda, MD 20892, USA. tandonp@mail.nih.gov
Nordstrom
Robert J
RJ
D000818:Animals; D003952:Diagnostic Imaging / Q000379:methods*; D053758:Nanoparticles / Q000032:analysis*; D036103:Nanotechnology; D014018:Tissue Distribution; D057170:Translational Research, Biomedical